EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY-NC-ND 4.0

Validation of International Classification of Diseases Code–Based Case Definitions of Immune Checkpoint Inhibitor–Associated Inflammatory Arthritis From Administrative Health Data

Manar Elsayed iD, Zoe Hsu iD, Finlay A McAlister iD, William D Leslie iD, Lisa M Lix iD, Sasha Bernatsky iD, Suzanne N Morin iD, Michelle M Graham iD, Aurore Fifi-Mah iD, Shahin Jamal iD, Janet Roberts iD, Carrie Ye iD

Arthritis & Rheumatology · 2026

DOI: 10.1002/art.70149 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Arthritis & Rheumatology, 2026. Verfasst von Manar Elsayed und 11 weiteren Autor:innen. Beteiligte Einrichtung: University of Alberta, Edmonton, Alberta, Canada. Hauptthemen laut MEDLINE: International Classification of Diseases, Immune Checkpoint Inhibitors, Arthritis, Neoplasms. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Carrie Ye was supported by a Canadian Institutes of Health Research Early Career Research Award, the Canadian Institutes of Health Research, Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Immune checkpoint inhibitors (ICIs) for cancer can lead to immune‐related adverse events, including ICI‐associated inflammatory arthritis (ICI‐IA). There are no validated International Classification of Diseases (ICD) code–based case definitions for ICI‐IA.

Methods

We conducted a validation study using the Canadian Research Group of Rheumatology in Immuno‐Oncology (CanRIO) database. Rheumatologist‐confirmed ICI‐IA was the reference standard, defined as new onset of at least one swollen joint on examination or synovitis on imaging following ICI exposure, without another cause or pre‐existing IA. We compared ICD‐9 (714.x and 696.0) and ICD‐10 (M05.x, M06.x, and M07.x) IA diagnostic codes against the reference standard. Seven core case definitions of different combinations of ICD codes from the Physician Claims Database (PCD) and the Discharge Abstract Database were tested. Results were stratified by sex. Sensitivity testing with additional criteria was also evaluated.

Results

We included 228 patients in the final analysis: 100 with ICI‐IA and 128 without ICI‐IA. Sensitivity of the tested case definitions ranged from 1.0% to 88.0%, whereas specificity ranged from 86.7% to 100.0%. The case definition with at least one PCD IA code achieved the best balance of sensitivity (88.0%, 95% confidence interval [CI] 81.6%–94.4%) and specificity (86.7%, 95% CI 80.8%–92.6%). Case definition performances were similar between sexes. Additional criteria minimally improved specificity but sacrificed sensitivity.

Conclusion

ICD code–based case definitions of ICI‐IA can accurately detect ICI‐IA and can be used to support ICI‐IA surveillance and research with administrative health data.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

International Classification of DiseasesImmune Checkpoint InhibitorsArthritisNeoplasmsHumansFemaleMaleDatabases, FactualAgedCanadaMiddle AgedSensitivity and Specificity

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • University of Alberta, Edmonton, Alberta, Canada.
  • Provincial Research Data Services, Alberta Health Services, Edmonton, Alberta, Canada.
  • Data and Research Services, Alberta SPOR SUPPORT Unit, Edmonton, Canada.
  • University of Manitoba, Winnipeg, Manitoba, Canada.
  • McGill University, Montreal, Quebec, Canada.
  • University of Calgary, Calgary, Alberta, Canada.

ORCID-Profile: Manar Elsayed, Zoe Hsu, Finlay A McAlister, William D Leslie, Lisa M Lix, Sasha Bernatsky, Suzanne N Morin, Michelle M Graham, Aurore Fifi-Mah, Shahin Jamal, Janet Roberts, Carrie Ye

Förderung

  • Carrie Ye was supported by a Canadian Institutes of Health Research Early Career Research Award
  • the Canadian Institutes of Health Research
  • Canadian Institutes of Health Research

Zitieren

APA

Elsayed, M., Hsu, Z., McAlister, F. A., Leslie, W. D., Lix, L. M., Bernatsky, S., Morin, S. N., Graham, M. M., Fifi-Mah, A., Jamal, S., Roberts, J., & Ye, C. (2026). Validation of International Classification of Diseases Code–Based Case Definitions of Immune Checkpoint Inhibitor–Associated Inflammatory Arthritis From Administrative Health Data. Arthritis & Rheumatology. https://doi.org/10.1002/art.70149

Vancouver

Elsayed M, Hsu Z, McAlister FA, Leslie WD, Lix LM, Bernatsky S, et al. Validation of International Classification of Diseases Code–Based Case Definitions of Immune Checkpoint Inhibitor–Associated Inflammatory Arthritis From Administrative Health Data. Arthritis & Rheumatology. 2026. doi:10.1002/art.70149

BibTeX
@article{Elsayed2026,
  author = {Elsayed, Manar and Hsu, Zoe and McAlister, Finlay A and Leslie, William D and Lix, Lisa M and Bernatsky, Sasha and Morin, Suzanne N and Graham, Michelle M and Fifi-Mah, Aurore and Jamal, Shahin and Roberts, Janet and Ye, Carrie},
  title = {Validation of International Classification of Diseases Code–Based Case Definitions of Immune Checkpoint Inhibitor–Associated Inflammatory Arthritis From Administrative Health Data},
  journal = {Arthritis & Rheumatology},
  year = {2026},
  doi = {10.1002/art.70149}
}
Kostenlos starten →